CRISPR Therapeutics’ fourth quarter was relatively disappointing. As a biotech start-up still in its infancy though, these early quarterly numbers don’t mean much. The foreseeable future looks bright ...

In June, 2025, the Wellcome Trust announced an ambitious £10 million UK project called the Synthetic Human Genome Project (SynHG) and claimed it “will unlock a deeper understanding of life, leading to ...

Scientists at The University of Texas at Austin have developed a revolutionary gene-editing method using bacterial retrons that can correct multiple disease-causing mutations at once. Unlike ...

Nick is a freelance writer from Chicago, IL, with a BA in Creative Writing from the University of Illinois at Urbana-Champaign. His lifelong belief in the artistic power of video games led him to ...

DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...

Jan 28 (Reuters) - ‌U.S. drugmaker Eli Lilly signed an ‌agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on Wednesday, to develop and commercialize ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing company Seamless Therapeutics. This morning’s deal with Seamless centers on ...

What if a cup of coffee could help treat cancer? Researchers at the Texas A&M Health Institute of Biosciences and Technology believe it's possible. By combining caffeine with the use of CRISPR—a ...

CRISPR–Cas9 is a revolutionary gene-editing tool, adapted from this bacterial immune system, that has been widely explored for its clinical applications in recent times. While the CRISPR–Cas9 shows ...

Baby KJ was the first to receive a bespoke gene-editing treatment. Personalized drugs for others could be approved within the next few years. Kyle “KJ” Muldoon Jr. was born with a rare genetic ...

BOSTON--(BUSINESS WIRE)--Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing ...

Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU. Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013 ...